Vestibular dysfunction: a frequent problem for adults with mitochondrial disease

INTRODUCTION
Mitochondrial diseases are a diverse group of genetic disorders caused by mutations in nuclear-encoded and mitochondrial DNA (mtDNA)-encoded genes. Disturbance in balance is common in adults with mitochondrial disease and usually attributed to an underlying peripheral neuropathy, skeletal myopathy and/or cerebellar disease, with limited treatment options. The vestibular system is central to balance control, and vestibular dysfunction causes vertigo, dizziness, oscillopsia, unsteadiness, and associated falls. Reports of vestibular dysfunction in mitochondrial disease are confined to small patient cohorts with limited and/or inconsistent use of neuro-otological assessments.\(^1\text{-}^3\) Furthermore, despite the well-recognised association with hearing loss,\(^2\) the frequency and underlying pathophysiological basis of vestibular dysfunction in mitochondrial disease is currently unknown.

We have undertaken a large-scale, cross-sectional cohort study investigating the prevalence, classification and predictors of vestibular dysfunction in adults with mitochondrial disease.

PATIENTS AND METHODS
All procedures were conducted as part of routine clinical care. The study was performed under the ethical guidelines..."
issued by our institution, with written informed consent obtained from all participants for genetic studies. We included adults (aged 16 years or older) attending our specialist clinic between May 2016 and August 2017 with clinico-pathologically and/or genetically confirmed mitochondrial disease and a suspected balance disorder. This cohort was subsequently evaluated by a specialist neuromuscular physiotherapist (SH) to exclude non-vestibular balance disorders. Patients with suspected vestibulopathy were subsequently referred for neuro-otological investigations (online supplementary table 1). Descriptive analyses were conducted on patient demographics, reported symptoms, neuro-otological and mitochondrial diagnoses, Newcastle Mitochondrial Disease Scale for Adults (NMDAS; a semiquantitative clinical rating scale for mitochondrial disease aimed at providing a validated and reproducible measurement of disease progression) total scores, hearing observations and mtDNA mutation load. NMDAS vision, hearing and balance-related subdomain scores were presented as median and IQR for those with and without neuro-otological diagnoses and for patients harbouring the m.3243A>G mutation in MT-TL1. The predictive value of patient-reported symptoms and hearing loss was investigated using Pearson χ² analyses and risk ratios (±95% CIs). A univariate logistic regression analysis was performed to investigate whether total NMDAS or NMDAS subdomain scores could predict neuro-otological diagnoses (peripheral or central). A Mann-Whitney test compared NMDAS scores in individuals with and without a neuro-otological diagnosis. Spearman’s correlation testing explored relationships between m.3243A>G mutant load and NMDAS total score. Statistical significance was set at p<0.05.

RESULTS

One hundred and fourteen patients with clinicopathologically and/or genetically confirmed mitochondrial disease were evaluated during the study period. Of these, 35% (40/114) with a suspected balance disorder were referred for a physiotherapy assessment (table 1). This revealed that patient-reported symptoms clustered into five major domains: (1) dizziness; (2) light-headedness; (3) loss of balance; (4) unsteadiness and (5) falls. Five patients were diagnosed with a pure cerebellar syndrome and two with a biomechanical cause for falls. The remaining patients underwent neuro-otological investigations and a vestibular abnormality was detected in 91% (30/33), of which 77% (23/30) had peripheral vestibulopathy (table 1 and online supplementary table 1).

Eighty-two per cent (27/33) of patients who received neuro-otological testing had sensorineural hearing loss (SNHL), with coexistent peripheral vestibulopathy in 74% (20/27). The hearing loss was bilateral in the majority (18/20). However, bilateral peripheral vestibulopathy was present in only 53% (11/20).

An increased risk of vestibular dysfunction was identified in patients reporting symptoms of dizziness (risk ratio (RR) 3.33), light-headedness (RR 4.67) and loss of balance (RR 1.56), while hearing loss predicted peripheral vestibulopathy (RR 2.22, online supplementary table 2). Mean NMDAS total score for the cohort was 24.88 (range 1.16–76.56). No significant difference was observed in NMDAS scores between participants with and without a neuro-otological diagnosis (Z=0.27, p=0.81) and NMDAS total and subscores were not predictive of a neuro-otological diagnosis (online supplementary table 3 and online supplementary table 4).

DISCUSSION

We present the first large-scale cohort study of vestibular dysfunction in adults with mitochondrial disease. The overall minimum prevalence of vestibular pathology in our symptomatic cohort of adults with mitochondrial disease was 26% (30/114), of which 77% was diagnosed as peripheral vestibulopathy. Given the known predominance of mtDNA encoding gene mutations accounting for mitochondrial disease in adults, reflected in the genetic spectrum of our cohort, we suggest these findings should be primarily applied to mtDNA-related disorders.

SNHL and peripheral vestibulopathy coexisted in 74% (20/27) of patients. A substantial proportion of this group harboured the m.3243A>G mutation (60%, 12/20), frequently associated with hearing impairment. 2 Although bilateral SNHL was present in 78% (18/23) of patients with peripheral vestibulopathy, only 50% (9/18) had bilateral peripheral vestibulopathy. Furthermore, SNHL was present in seven patients without peripheral vestibulopathy. Taken together, these findings suggest SNHL and peripheral vestibulopathy progress at variable rates or have divergent pathophysiological mechanisms. Two patients with bilateral peripheral vestibulopathy had previously been diagnosed with unilateral peripheral vestibulopathy, suggesting a progressive decline in vestibular function. This is the first description of either bilateral or progressive vestibulopathy in patients with maternally inherited diabetes and deafness due to the m.3243A>G mutation. Benign paroxysmal positional vertigo (BPPV) was an additional neuro-otological finding in three patients. BPPV is often overlooked in patients with neurological comorbidities 4 and is a treatable, often curable, balance disorder.

The results of this study have informed the development of a framework to support the identification, investigation and management of balance disorders in adults with mitochondrial disease attending our specialist clinic (online supplementary figure 1). Prospective analysis will further validate the sensitivity and specificity of this algorithm and may have important implications for other complex neurological disorders associated with vestibular dysfunction.

This study confirms that vestibular dysfunction is an important manifestation of mitochondrial disease in adults. Given the clear benefits of vestibular rehabilitation, 3 identifying and diagnosing people with vestibular dysfunction is important to ensure appropriate and effective management of these disabling symptoms. Consequently, referral for neuro-otological assessment should be considered in all adults with mitochondrial disease reporting dizziness, unsteadiness or SNHL. Ongoing longitudinal analysis of our cohort is currently underway to determine the natural history of vestibular dysfunction in adults with mitochondrial disease.

Sarah Holmes,1 Amanda J Male,2 Gita Ramdhrarry,1 Cathy Woodward,3 Natalie James,1 Iwona Skorupinska,1 Mariola Skorupinska,1 Louise Germain,1 Damian Kozyra,1,4 Enrico Bugiardini,1,4 Olivia V Poole,1,5 Ros Quinilvan,1,5 Michael G Hanna,1,6 Diego Kaski,6 Robert D S Pitceathly1,4

1MRC Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK; 2Therapy Services, National Hospital for Neurology and Neurosurgery, London, UK; 3Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, UK; 4Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK; 5Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London, UK; 6Department of Neuro-Otology, University College London Hospitals, London, UK

Correction notice Since this paper was first published online affiliation 4 has been amended.
Table 1  Clinical, genetic and neuro-otological assessment findings in adults with mitochondrial disease and a suspected balance disorder

| Clinical phenotype | Genetic diagnosis | Gender | Age | NMDS score | Mitochondrial DNA mutant load | Primary neuro-otological diagnosis | Additional neuro-otological diagnoses | Patient-reported symptoms | Blood | Urine | Muscle | davon | Dizziness | Light-headed | Loss of balance | Unsteadiness | Falls | SNHL |
|--------------------|------------------|--------|-----|------------|-------------------------------|-----------------------------------|------------------------------------|-------------------------------------|-------|-------|--------|-------|----------|-------------|----------------|-------------|--------|------|
| MIDD | m.3243A>G MT-TL1 | F | 70 | 29 | 67 | Peripheral vestibulopathy (bilateral) | Vestibular migraine (central) | Y | Y | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 33 | 14.5 | 27 | Peripheral vestibulopathy (unilateral) | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 57 | 17.4 | 13 | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 69 | 24.36 | 6 | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 55 | 51.3 | No sample | BPPV | Y | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 60 | 35.4 | 19 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Bilateral |
| MELAS | m.3243A>G MT-TL1 | F | 46 | 12.76 | 23 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 42 | 23.6 | 21 | Peripheral vestibulopathy (unilateral) | BPPV | Y | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 50 | 16.1 | 22 | Peripheral vestibulopathy (bilateral) | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 50 | 30.1 | 20 | Vestibular migraine (central) | Y | Y | Y | Y | Bilateral |
| SNHL, RP, ataxia | m.3243A>G MT-TL1 | F | 65 | 27.44 | 14 | Peripheral vestibulopathy (unilateral) | Vestibular migraine (central) | Y | Y | Y | Y | Bilateral |
| SNHL | m.3243A>G MT-TL1 | F | 1.16 | 13 | Peripheral (unilateral) | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | F | 40 | 42.92 | 10 | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Bilateral |
| SNHL, RP, HCM | m.3243A>G MT-TL1 | F | 70 | 13.92 | 13 | Peripheral vestibulopathy (unilateral) | BPPV | Y | Y | Y | Bilateral |
| SNHL | m.3243A>G MT-TL1 | F | 50 | 6.2 | 22 | Peripheral vestibulopathy (bilateral) | Y | Y | Bilateral |
| MIDD | m.3243A>G MT-TL1 | M | 73 | 20.4 | 14 | Peripheral vestibulopathy (bilateral) | Y | Y | Bilateral |
| MERRF | m.3444A>G MT-TK | F | 43 | 14.5 | 60 | Peripheral vestibulopathy (bilateral) | BPPV | Y | Y | Y | Y | Right |
| MERRF | m.3444A>G MT-TK | M | 58 | 24.36 | No sample | Not investigated (cerebellar) | Y | Y | Y | Y | Bilateral |
| MERRF | m.3444A>G MT-TK | F | 43 | 7.8 | No sample | Not investigated (cerebellar) | Y | Y | Y | Bilateral |
| MERRF | m.3444A>G MT-TK | F | 55 | 31.31 | 75 | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Normal |
| MERRF | m.3444A>G MT-TK | F | 50 | 25.52 | No | Not investigated (cerebellar) | Y | Y | Y | Y | Bilateral |
| MERRF | m.3444A>G MT-TK | F | 69 | 60.32 | 60 | Peripheral vestibulopathy (bilateral) | Vestibular-cerebellar (central) | Y | Y | Y | Y | Normal |
| RP, SNHL, DM | m.12258C>A MT-TS2 | F | 50 | 19.56 | 30 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Bilateral |
| MDS, NIKHD | m.7182G>T MT-ATP6 | M | 37 | 20.88 | 31 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Bilateral |
| Ataxia, neuropathy | m.5178T>C MT-ATP6 | M | 29 | 27.44 | 100 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Bilateral |
| HCM, NHSH, ataxia | m.1553A>G MT-MB1 | M | 62 | 17.2 | 100 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Normal |
| RP, SNHL | m.10038G>A MT-TG | F | 42 | 26.88 | 15 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Bilateral |
| Leigh syndrome | m.3041T>C MT-NOS | M | 24 | 20.88 | 38 | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Normal |
| CPEO, ataxia | Multiple mtDNA deletions | F | 57 | 40.6 | N/A | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Normal |
| MDS, SH, NIKHD | Multiple mtDNA deletions | M | 64 | 15.56 | N/A | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Bilateral |
| MDS, NIKHD | Multiple mtDNA deletions | M | 64 | 19.7 | N/A | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Bilateral |
| CPEO, SH, NIKHD | Multiple mtDNA deletions | M | 57 | 36.5 | N/A | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Normal |
| CPEO | Single mtDNA deletion | M | 63 | 16.24 | N/A | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Normal |
| CPEO | Single mtDNA deletion | F | 26 | 16.24 | N/A | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Normal |
| CPEO, ataxia | POLG | M | 60 | 31.32 | N/A | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Bilateral |
| SNHL, DM | CORF8 | F | 42 | 13.92 | N/A | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Bilateral |
| CPEO | Chronic progressive external ophthalmoplegia | F | 44 | 12.38 | N/A | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Bilateral |
| CPEO | Chronic progressive external ophthalmoplegia | M | 40 | 21.35 | N/A | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Bilateral |
| CPEO | Chronic progressive external ophthalmoplegia | M | 45 | 11.6 | N/A | Peripheral vestibulopathy (unilateral) | Y | Y | Y | Y | Bilateral |
| Multisystem | Chronic progressive external ophthalmoplegia | F | 32 | 29 | N/A | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Normal |
| SNHL, DM, ptosis | Chronic progressive external ophthalmoplegia | F | 72 | 29 | N/A | Peripheral vestibulopathy (bilateral) | Y | Y | Y | Y | Bilateral |

Mitochondrial DNA (mtDNA) mutant load describes the percentage of mutant mtDNA in the tissue analysed. Higher scores using the Newcastle Mitochondrial Disease Scale for Adults (NMDAS) indicates greater disease burden. BPPV, benign paroxysmal positional vertigo; COX, cytochrome c oxidase; CPEO, chronic progressive external ophthalmoplegia; DM, diabetes mellitus; EI, exercise intolerance; f, female; HCM, hypertrophic cardiomyopathy; MIDD, maternally inherited diabetes and deafness; RP, retinitis pigmentosa; SNHL, sensorineural hearing loss; Y, yes.

Copyright.

Published on September 7, 2021 by guest. Protected by
Contributors SH and AJM are joint primary investigators and coauthors. DK and RDSP are joint primary investigators and coauthors. All authors contributed to the conception or design of the work or the acquisition, analysis or interpretation of data. All authors were involved in drafting the work or revising it critically and reviewing for final approval. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding This study was supported by a Medical Research Council Centre grant (G0601943). Part of this work was undertaken in the University College London Hospitals/University College London Queen Square Institute of Neurology sequencing facility, which received a proportion of funding from the Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme. OP has received funding from the Lily Foundation. DK is supported by the National Institute for Health Research University College London Biomedical Research Centre. The clinical and diagnostic mitochondrial service in London is funded by the UK NHS Highly Specialised Commissioners to provide the “Rare Mitochondrial Disorders” Service.

Competing interests None declared.

Patient consent Not required.

Ethics approval Queen Square.

Provenance and peer review Not commissioned; externally peer reviewed.

OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix and transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.

Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/jnnp-2018-319267).

SH and AJM are joint first authors.

DK and RDSP are joint last authors.

To cite Holmes S, Male AJ, Ramdharry G, et al. J Neurol Neurosurg Psychiatry 2019;90:838–841.

Received 19 July 2018
Revised 5 October 2018
Accepted 11 October 2018
Published Online First 26 November 2018

J Neurol Neurosurg Psychiatry 2019;90:838–841.
doi:10.1136/jnnp-2018-319267

REFERENCES

1. Cardenas-Robledo S, Saber Tehrani A, Blume G, et al. Visual, ocular motor, and cochleo-vestibular loss in patients with heteroplasmic, maternally-inherited diabetes mellitus and deafness (MIDD). 3243 transfer RNA mutation. J Neuropathol 2016;36:134–40.
2. Iwasaki S, Egami N, Fujimoto C, et al. The mitochondrial A3243G mutation involves the peripheral vestibule as well as the cochlea. Laryngoscope 2011;121:1821–4.
3. Kim SH, Akbarทดjaeva ZA, Jung J, et al. Eye movement and vestibular dysfunction in mitochondrial A3243G mutation. Neurosci 2016;37:1159–62.
4. Frohman EM, Kramer PD, Dewey RB, et al. Benign paroxysmal positioning vertigo in multiple sclerosis: diagnosis, pathophysiology and therapeutic techniques. Mult Scler 2003;9:250–5.
5. Hall CD, Herdman SJ, Whitney SL, et al. Vestibular rehabilitation for peripheral vestibular hypofunction: an evidence-based clinical practice guideline: from the American physical therapy association neurology section. J Neurol Phys Ther 2016;40:124–55.